NeOnc Technologies Holdings, Inc. (NTHI) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-31
How it makes money
It plans to generate profit by using intranasal delivery of NEO100 to bypass the blood-brain barrier for patients with recurrent Grade IV malignant glioma.
It aims to profit by delivering NEO100, a purified monoterpenoid, through an intranasal route to treat malignant gliomas and meningiomas.
This method is designed to bypass the blood-brain barrier, a physiological hurdle that previously caused oral formulations of the same compound to fail in clinical trials.
Profitability depends on successfully completing Phase II trials for patients with IDH1 mutations, where the drug has shown preliminary response rates exceeding historical salvage therapy benchmarks.
What protects it: the moat
It relies on Orphan Drug Designations granted in 2011 and 2014 to secure exclusive marketing rights for its intranasal and conjugated drug candidates.
It maintains a competitive barrier through Orphan Drug Designations for its lead candidates, which offer seven years of market exclusivity upon regulatory approval.
The business also holds intellectual property covering 3D bioprinting and AI-driven drug discovery tools used to model patient-specific tumor responses to therapy.
Management claims the intranasal delivery platform provides a unique safety advantage by allowing patients to self-administer treatments at home using standard nebulizers.
What could damage it
It faces risks to its going concern status due to financing with a 40% original issue discount and total accumulated deficit of $112,754,655.
It faces a liquidity risk described by auditors as a substantial doubt about its ability to continue as a going concern.
The company relies on high-interest financing, including convertible notes that have required extensions increasing the original issue discount to 40%.
Failure to secure non-dilutive funding or achieve positive clinical milestones could prevent the company from meeting its debt obligations or maintaining its Nasdaq listing.
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.